Trial Profile

Phase 2, multicenter, randomized, double blind, active placebo controlled clinical trial of SYNP-101 for obsessive-compulsive disorder

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary) ; Niacin
Indications Obsessive-compulsive disorders
Focus Therapeutic Use
Sponsors Ceruvia Lifesciences

Most Recent Events

27 Jun 2022 According to a Ceruvia Lifesciences media release, the USA Food and Drug Administration (FDA) has approved its Investigational New Drug application for this study.
27 May 2022 New trial record
24 May 2022 According to a Ceruvia Lifesciences media release, this study will led by Principal Investigators Dr. Benjamin Kelmedi and Dr. Christopher Pittenger of Yale University School of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com